A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cemiplimab (Primary) ; Cisplatin (Primary) ; Fianlimab (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

15 Jul 2024 Planned initiation date changed from 5 Mar 2024 to 2 Aug 2024.
03 Jun 2024 Status changed from not yet recruiting to recruiting.
02 Feb 2024 According to a Regeneron Pharmaceuticals media release, the company expects to initiate this potentially pivotal trial in first half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight